TG Therapeutics (TGTX) Competitors $45.37 -0.14 (-0.31%) Closing price 04:00 PM EasternExtended Trading$45.09 -0.28 (-0.62%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX vs. ONC, SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, and QGENShould you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Beigene (ONC), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. TG Therapeutics vs. Beigene Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen TG Therapeutics (NASDAQ:TGTX) and Beigene (NASDAQ:ONC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk. Do insiders & institutionals believe in TGTX or ONC? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by company insiders. Comparatively, 6.6% of Beigene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor TGTX or ONC? TG Therapeutics received 650 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 76.27% of users gave TG Therapeutics an outperform vote while only 75.00% of users gave Beigene an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65976.27% Underperform Votes20523.73% BeigeneOutperform Votes975.00% Underperform Votes325.00% Does the media refer more to TGTX or ONC? In the previous week, TG Therapeutics had 4 more articles in the media than Beigene. MarketBeat recorded 17 mentions for TG Therapeutics and 13 mentions for Beigene. TG Therapeutics' average media sentiment score of 1.34 beat Beigene's score of 0.44 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beigene 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate TGTX or ONC? TG Therapeutics presently has a consensus price target of $40.67, suggesting a potential downside of 10.64%. Beigene has a consensus price target of $318.88, suggesting a potential upside of 22.73%. Given Beigene's stronger consensus rating and higher possible upside, analysts clearly believe Beigene is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Beigene 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TGTX or ONC more profitable? TG Therapeutics has a net margin of -5.42% compared to Beigene's net margin of -25.94%. TG Therapeutics' return on equity of -8.32% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Beigene -25.94%-25.12%-14.95% Which has more volatility and risk, TGTX or ONC? TG Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Which has stronger valuation & earnings, TGTX or ONC? TG Therapeutics has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329.00M21.96$12.67M$0.14325.07Beigene$3.81B6.74-$881.71M-$6.14-42.31 SummaryTG Therapeutics beats Beigene on 13 of the 18 factors compared between the two stocks. Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TGTX vs. The Competition Export to ExcelMetricTG TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.23B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-455.057.4422.4818.48Price / Sales21.96242.70394.56103.59Price / Cash353.9065.8538.1834.62Price / Book42.936.516.774.25Net Income$12.67M$143.21M$3.22B$248.23M7 Day Performance12.93%1.98%1.48%0.89%1 Month Performance20.56%6.89%3.99%3.53%1 Year Performance186.59%-2.52%16.15%5.08% TG Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TGTXTG Therapeutics3.3177 of 5 stars$45.37-0.3%$40.67-10.4%+233.2%$7.20B$329.00M-453.65290Upcoming EarningsNews CoveragePositive NewsONCBeigene2.0064 of 5 stars$229.22-0.8%$316.71+38.2%N/A$22.66B$3.81B-27.829,000Analyst ForecastAnalyst RevisionSMMTSummit Therapeutics2.6818 of 5 stars$25.22+2.5%$35.40+40.4%+513.7%$18.60B$700,000.00-90.07110Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries3.2705 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst UpgradeAnalyst RevisionPositive NewsGap UpITCIIntra-Cellular Therapies0.8793 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4448 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8404 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsPositive NewsASNDAscendis Pharma A/S2.3124 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Earnings ReportNews CoveragePositive NewsMRNAModerna4.4332 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.8326 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6881 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst Revision Related Companies and Tools Related Companies Beigene Alternatives Summit Therapeutics Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TGTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TGTX Stock Free TGTX Stock Alerts